Charles River Laboratories International, Inc. (NYSE: CRL) has announced the resignation of Flavia H. Pease, Corporate Executive Vice President and Chief Financial Officer (CFO), effective September 29, 2025, to pursue another opportunity. Following Pease's departure, Michael G. Knell, Corporate Senior Vice President and Chief Accounting Officer, will serve as interim CFO until a successor is named. The company has commenced a comprehensive search to identify its next CFO.
The company is reaffirming its 2025 financial guidance for revenue and non-GAAP earnings per share, supported by its current outlook for third-quarter performance. The press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share, excluding charges, gains, and losses attributable to businesses or properties the company plans to close, consolidate, or divest, among other adjustments related to acquisitions and divestitures.
The company's Q3 2025 revenue and non-GAAP EPS guidance have been reaffirmed, and Michael G. Knell has been appointed interim CFO following the resignation of Flavia H. Pease. The company is also actively seeking a replacement for the CFO position. As a result of these announcements, the company's shares have moved -0.25% on the market, and are now trading at a price of $151.855. If you want to know more, read the company's complete 8-K report here.
